Aug. 29 (Bloomberg) -- Pfizer Inc.’s and Bristol-Myers Squibb Co.’s Eliquis will lead the market for stroke-preventing blood thinners after “best-in-class” clinical trial results that marry safety with effectiveness, analysts said.
The twice-daily pill had a 31 percent lower risk of major bleeding, a feared side effect of blood thinners, than the current standard treatment, warfarin, researchers said yesterday at the European Society of Cardiology’s conference in Paris. Patients on Eliquis had an 11 percent reduced risk of dying, the first time a warfarin replacement has saved lives in a study.
Pfizer and Bristol-Myers may now take 60 percent of the market for blood thinners to ward off strokes in people with an irregular heartbeat, according to analysts for ISI Group and Leerink Swann & Co. Leerink estimates sales of warfarin replacements will reach $7 billion to $9 billion a year.
“The bleeding profile is phenomenal and trumps everything else,” Mark Schoenebaum, a New York-based analyst for ISI, said in a telephone interview. “Clearly, this drug will be the leader in the market.”
Yesterday’s results may mean an additional $1.1 billion in peak sales for Eliquis, also known as apixaban, Leerink’s Seamus Fernandez said in a report to investors today. The Boston-based analyst now forecasts the drug will garner revenue of $4.2 billion by 2017, writing that it’s “best-in-class” for safety and reducing deaths.
Pfizer rose 67 cents, or 3.7 percent, to $18.88 at 4 p.m. in New York Stock Exchange composite trading. Bristol-Myers climbed 57 cents, or 2 percent, to $29.29.
Pfizer and Bristol-Myers trailed two competitors in the race to bring a warfarin replacement to market. Boehringer Ingelheim GmbH’s Pradaxa was the first, approved last year in the U.S. Bayer AG and Johnson & Johnson also have a candidate, Xarelto, due for regulatory review in the U.S. next month.
Until the Paris conference, the two U.S. drugmakers had only compared Eliquis with aspirin. Now cardiologists have results of two large trials showing the drug is safe, a potentially compelling argument, said Lars Wallentin, a cardiologist at Uppsala Clinical Research Center in Sweden who worked on both Eliquis and Pradaxa.
“There is an edge to apixaban, I would admit,” Wallentin said in an interview at the conference.
Irregular heartbeat, or atrial fibrillation, is the biggest part of the market for Eliquis and its competitors. Other smaller groups of patients, such as people who’ve had hip and knee surgery, could generate an additional $3 billion to $6 billion in sales a year, Fernandez said.
Eliquis also prevented 21 percent more strokes than warfarin in the Aristotle study presented yesterday. For every 1,000 patients treated during the trial, it prevented a stroke in six people, major bleeding in 15 people and death in eight people, investigators wrote in a New England Journal of Medicine article published to coincide with the presentation in Paris. Pfizer and Bristol-Myers funded the research, which followed 18,200 patients.
“The answer is crystal clear: patients will do better on this drug,” lead investigator Christopher Granger, of the Duke Clinical Research Institute in Durham, North Carolina, said in an interview at the conference. Lower cost is the only reason for patients to continue taking warfarin, he said.
Doctors had been eager for a replacement for warfarin because patients need regular blood tests to ensure they’re getting a safe, effective dose of the older drug.
Eliquis was especially impressive because there was evidence it beat warfarin even in patients who were getting the optimal dose, Harvard University cardiologist Elliott Antman said in an interview. Antman is leading studies of another potential competitor, Daiichi Sankyo Co.’s edoxaban.
If a patient is stable on warfarin and doesn’t mind a monthly doctor’s visit for a blood test, there may be no reason to switch to a new, more expensive medicine, Ralph Brindis, senior adviser for cardiovascular disease at Northern California Kaiser Permanente, said in an interview. Warfarin, a generic drug, costs $4 a month, plus about $20 for blood tests, according to a January presentation by the University of Utah Health Care Thrombosis Service.
Atrial fibrillation occurs when the upper chambers of the heart quiver rather than contract, allowing blood to pool and form clots. More than 2.5 million Americans suffer from it, and 11,000 die every year.
Pradaxa and Xarelto didn’t significantly extend patients’ lives in studies, though both showed a trend toward being able to do so, Jessica Mega, a cardiologist at Brigham and Women’s Hospital in Boston, wrote in an editorial published alongside the results in the journal. Yet all three appear to be better on some measure than warfarin, Mega wrote.
Boehringer’s Pradaxa has the most to lose from good Eliquis results, Larry Biegelsen, a New York-based analyst for Wells Fargo Securities, wrote in a note to clients before the study was published. Bayer’s Xarelto was studied in a more high-risk group of patients than Eliquis or Pradaxa and could maintain a market niche because it’s a once-daily pill, Biegelsen said.
Warfarin is also once-daily. Both Eliquis and Pradaxa must be taken twice each day.
Pfizer and Bristol-Myers plan to submit Eliquis for U.S. and European regulatory approval by year-end.
Bristol-Myers and Pfizer “are two of the best cardiovascular marketers out there,” Leerink’s Fernandez said. “Put this together with the data, and you have a clear winner.”
To contact the editor responsible for this story: Phil Serafino at email@example.com